The first in vitro diagnostic test to detect brain plaques tied to Alzheimer’s disease can now be marketed to clinicians, the Food and Drug Administration announced this week. The Lumipulse G ...
REDMOND, Wash.--(BUSINESS WIRE)--Anavasi Diagnostics, an NIH/RADx funded medical technology company developing novel molecular diagnostic testing for the point-of-care (POC) market, announced the Food ...
Researchers develop a 96% accurate AI-powered retinal scan to distinguish between Alzheimer’s and ALS by detecting specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results